Hyperparathyroidism Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Hyperparathyroidism clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 3

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Chronic Kidney DiseaseSecondary Hyperparathyroidism
Amgen56 enrolled43 locationsNCT03633708
Recruiting
Phase 3

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism
Amgen24 enrolled23 locationsNCT03969329
Recruiting

Natural History Study of Parathyroid Disorders

Multiple Endocrine Neoplasia Type 1Primary HyperparathyroidismParathyroid Cancer+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)3,000 enrolled1 locationNCT04969926
Recruiting

Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors

Primary HyperparathyroidismParathyroid Gland CarcinomaParathyroid Gland Atypical Adenoma+1 more
M.D. Anderson Cancer Center310 enrolled1 locationNCT03039439
Recruiting

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

Heart FailureSarcopeniaOsteoporosis+11 more
Bettina Mittendorfer100 enrolled1 locationNCT07083557
Recruiting
Phase 3

Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism, Chronic Kidney Disease
Shaanxi Micot Pharmaceutical Technology Co., Ltd.424 enrolled1 locationNCT07122401
Recruiting

Precision Medicine Approaches to Renal Osteodystrophy

Chronic Kidney DiseasesCkd-MbdSecondary Hyperparathyroidism+2 more
Thomas Nickolas40 enrolled1 locationNCT05880914
Recruiting

Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder)

Thyroid NeoplasmsHyperparathyroidismParathyroid Gland
Bo Wang,MD180 enrolled1 locationNCT07010380
Recruiting
Phase 2

Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Shaanxi Micot Pharmaceutical Technology Co., Ltd.310 enrolled1 locationNCT06976177
Recruiting

Parathyroid Tumor Clonal Status

Primary HyperparathyroidismParathyroid Tumor
Washington University School of Medicine839 enrolled3 locationsNCT05997810
Recruiting

A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.

Chronic Kidney Disease 5DSecondary Hyperparathyroidism
Boryung Pharmaceutical Co., Ltd1,000 enrolled1 locationNCT06126016
Recruiting

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

Neuroendocrine NeoplasmParagangliomaPheochromocytoma+23 more
Universidad Nacional Autonoma de Mexico750 enrolled3 locationsNCT06523582